This clinical trial is currently in the recruitment phase, not the completion phase. NCT04085315 is a Phase 1/1b study led by Collin Blakely at the University of California, San Francisco (UCSF), initiated in November 2019. It aims to enroll 38 patients with Stage 4 EGFR-mutated non-small cell lung cancer. According to the ClinicalTrials.gov record updated in June 2024, the study is currently recruiting. Both the primary completion date and the study completion date are projected for December 31, 2026. Therefore, this event should be interpreted as an update on the progress of a dose-exploration study, rather than the completion of the trial or the confirmation of safety. The maximum tolerated dose (MTD) is defined as the highest dose level at which dose-limiting toxicities (DLTs) are observed in one or fewer of the six patients.

Alisertib (MLN8237) is a selective Aurora Kinase A (AURKA) inhibitor developed by Takeda Pharmaceutical (TAK) and is currently in the clinical stage without an approved brand name. In the trial, patients receive 20-50mg of alisertib twice daily on days 1-3, 8-10, and 15-17 of a 28-day cycle, and 80mg of Tagrisso (osimertinib) daily. Tagrisso is a mutant EGFR tyrosine kinase inhibitor. The combination aims to overcome resistance to osimertinib by targeting AURKA, as AURKA and its co-factor TPX2 are involved in bypass pathways that allow cancer cells to survive after EGFR inhibition. The primary goal is not to replace osimertinib, but to resensitize resistant tumors. The study also explores the correlation between TPX2 immunohistochemistry positivity and response to validate a biomarker hypothesis for future clinical trials.

The commercial scale and competitive intensity of the standard treatment are significant. Tagrisso, from AstraZeneca (AZN), received its initial FDA approval on November 13, 2015, and its approval for first-line treatment of EGFR exon 19 deletion or exon 21 L858R advanced non-small cell lung cancer was expanded on April 18, 2018. On February 16, 2024, the combination with platinum-based chemotherapy and pemetrexed was also approved. In 2025, global sales reached $7.254 billion, demonstrating the commercial potential of this indication. In the United States, EGFR mutations are present in approximately 20% of NSCLC patients, while in Asian patients, the prevalence is around 50%, resulting in a significantly different patient population across regions. For the alisertib combination to be successful, it must demonstrate superior efficacy and manageable myelosuppression compared to Tagrisso alone or in combination with chemotherapy.

The criteria for competition have already shifted to Phase 3 trials and approved products. The combination of lazertinib (Lazcluze, an EGFR inhibitor) and amivantamab-vmjw (Rybrevant, an EGFR/MET inhibitor) from Johnson & Johnson (JNJ) received FDA approval for first-line treatment on August 19, 2024. In the Phase 3 MARIPOSA trial, the median progression-free survival (PFS) was 23.7 months, compared to 16.6 months for Tagrisso, with a hazard ratio of 0.70 and a p-value of 0.0002. After osimertinib treatment, Rybrevant in combination with carboplatin and pemetrexed, as well as datopotamab deruxtecan-dlnk (Datroway, a TROP2 ADC) from Daiichi Sankyo, are also included in the competitive landscape for FDA approval. This early study of 38 patients is valuable for establishing a recommended dose, assessing safety, and identifying potential response signals and the possibility of TPX2-based patient selection, rather than providing a basis for commercialization.